Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study

Treatment-free remission (TFR) has become a primary therapeutic goal in CML and is also considered feasible by international guidelines. TKIs dose reduction is often used in real-life practice to reduce adverse events, although its impact on TFR is still a matter of debate. This study aimed to explo...

Descripción completa

Detalles Bibliográficos
Autores principales: Iurlo, Alessandra, Cattaneo, Daniele, Artuso, Silvia, Consonni, Dario, Abruzzese, Elisabetta, Binotto, Gianni, Bocchia, Monica, Bonifacio, Massimiliano, Castagnetti, Fausto, Galimberti, Sara, Gozzini, Antonella, Iezza, Miriam, Latagliata, Roberto, Luciano, Luigiana, Maggi, Alessandro, Miggiano, Maria Cristina, Pregno, Patrizia, Rege-Cambrin, Giovanna, Russo, Sabina, Scortechini, Anna Rita, Tafuri, Agostino, Tiribelli, Mario, Fava, Carmen, Rosti, Gianantonio, Foa, Robin, Breccia, Massimo, Saglio, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927081/
https://www.ncbi.nlm.nih.gov/pubmed/35311109
http://dx.doi.org/10.3389/fonc.2022.839915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927081/
https://www.ncbi.nlm.nih.gov/pubmed/35311109
http://dx.doi.org/10.3389/fonc.2022.839915

Ejemplares similares